Here's our initial take on Novocure's (NVCR -17.02%) fiscal 2025 second-quarter financial report.
| Metric | Q2 2024 | Q2 2025 | Change | vs. Expectations |
|---|---|---|---|---|
| Revenue | $150.4 million | $158.8 million | 6% | Beat |
| Earnings per share | -$0.31 | -$0.36 | N/A | Beat |
| Gross margin | 77% | 74% | -300 bp | n/a |
| Total active patients | 3,963 | 4,331 | 9% | n/a |
Novocure reported no surprises in its latest quarter, with revenue up 6% for the year and both revenue and loss per share topping Wall Street expectations. The company, which is developing noninvasive methods to treat solid-tumor cancers, has added more than 300 active patients to its trials over the last year.
Revenue from its Optune Lua lung cancer treatment, which was approved for use in the U.S. last fall, totaled $2.4 million.
Gross margin fell by 300 basis points in the quarter, which the company attributed to costs associated with the rollout of new products. Research, development, and clinical studies expenses in the quarter totaled $55.8 million, up 2% from the same period in 2024.
Although Novocure is not yet profitable, the company ended the quarter with $911.5 million in cash and equivalents on the books.
The results were largely in line with expectations, and there hasn't been a strong market reaction on Thursday morning. Novocure stock was up about 2% in premarket trading.
CEO Ashley Cordova called it "a pivotal period for Novocure." Before year's end, the company plans to seek Food and Drug Administration (FDA) premarket approval for the treatment of certain types of pancreatic cancer and a separate treatment for brain cancers based on phase 3 trial data. Data from trials on treating metastatic pancreatic cancer and glioblastoma are expected in the first half of 2026.
Of course, Novocure investors know better than most that there are no "sure things" in biotech. The stock is trading down more than 92% from its 2021 high due to disappointing results from a once-promising lung cancer trial.
Novocure offers great potential but also significant risk. The latest results reinforce the potential and show the company remains on track, but the ultimate trajectory of this stock remains very much tied to how these trials and FDA applications progress.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。